Literature DB >> 18178914

Renal radiosurgery: initial clinical experience with histological evaluation.

Lee E Ponsky1, Arul Mahadevan, Indebir S Gill, Toufik Djemil, Andrew C Novick.   

Abstract

The purpose of this study was to determine whether radiosurgical technology can be safely applied to renal tumors. Patients received radiosurgical treatment of renal lesions. At 8 weeks after radiosurgical treatment, patients underwent a partial or radical nephrectomy and histologic evaluation. The patients received a radiation dose of 4 Gy per fraction for 4 fractions. Patients were followed, and radiation-induced toxicities were noted. Three patients were treated for a minimum of 1 year of follow-up. All patients completed the treatments, tolerating each of the 4 fractions with no adverse events. No acute toxicities or changes in renal function were noted. None of the patients had any evidence of acute radiation injury or toxicity noted at the time of surgery or within the subsequent 12 months after the radiosurgical treatment. The last patient treated was found to have a cavity with no microscopic evidence of viable tumor after radiosurgical treatment; pathology was consistent with necrotic renal cell carcinoma, papillary type. The other 2 tumors demonstrated pathologic evidence of viable renal cell carcinoma (grade I and grade II). Tumor size remained relatively unchanged for 8 weeks after the radiosurgical treatment in all patients. The authors are extremely encouraged and cautiously optimistic with the initial results. Radiosurgery for renal tumors appears to be safe at this initial dose level.

Entities:  

Mesh:

Year:  2007        PMID: 18178914     DOI: 10.1177/1553350607310546

Source DB:  PubMed          Journal:  Surg Innov        ISSN: 1553-3506            Impact factor:   2.058


  10 in total

Review 1.  Extracorporeal stereotactic radiosurgery for small renal masses.

Authors:  Gino J Vricella; Nicholas A Boncher; Lee E Ponsky
Journal:  Curr Urol Rep       Date:  2010-02       Impact factor: 3.092

2.  A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.

Authors:  Anurag K Singh; Timothy B Winslow; Mohammad Habiby Kermany; Vincent Goritz; Lilia Heit; Austin Miller; Nicholas C Hoffend; Leighton C Stein; Lalith K Kumaraswamy; Graham W Warren; Wiam Bshara; Kunle Odunsi; Junko Matsuzaki; Scott I Abrams; Thomas Schwaab; Jason B Muhitch
Journal:  Clin Cancer Res       Date:  2017-06-19       Impact factor: 12.531

Review 3.  To combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma.

Authors:  Christian Weiss; Björn Schulze; Annette Ottinger; Claus Rödel
Journal:  World J Urol       Date:  2013-05-08       Impact factor: 4.226

4.  Effect of Stereotactic Body Radiotherapy on the Growth Kinetics and Enhancement Pattern of Primary Renal Tumors.

Authors:  Maryellen R M Sun; Alexander Brook; Michael F Powell; Krithica Kaliannan; Andrew A Wagner; Irving D Kaplan; Ivan Pedrosa
Journal:  AJR Am J Roentgenol       Date:  2016-03       Impact factor: 3.959

Review 5.  Stereotactic body radiation therapy: a novel treatment modality.

Authors:  Simon S Lo; Achilles J Fakiris; Eric L Chang; Nina A Mayr; Jian Z Wang; Lech Papiez; Bin S Teh; Ronald C McGarry; Higinia R Cardenes; Robert D Timmerman
Journal:  Nat Rev Clin Oncol       Date:  2009-12-08       Impact factor: 66.675

6.  A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases.

Authors:  Jeffrey J Meyer; Ryan D Foster; Naama Lev-Cohain; Takeshi Yokoo; Ying Dong; Roderich E Schwarz; William Rule; Jing Tian; Yang Xie; Raquibul Hannan; Lucien Nedzi; Timothy Solberg; Robert Timmerman
Journal:  Ann Surg Oncol       Date:  2015-05-12       Impact factor: 5.344

7.  Renal cell carcinoma treated with stereotactic radiotherapy with histological change confirmed on autopsy: a case report.

Authors:  Hiroshi Onishi; Tomonori Kawasaki; Hidenori Zakoji; Takashi Yoshida; Takafumi Komiyama; Kengo Kuriyama; Masayuki Araya; Ryo Saito; Shinichi Aoki; Yoshiyasu Maehata; Licht Tominaga; Kan Marino; Iori Watanabe; Mitsuhiko Oguri; Tsutomu Araki; Nobuyuki Enomoto; Masayuki Takeda; Ryohei Katoh
Journal:  BMC Res Notes       Date:  2014-04-26

8.  Renal Cancer is Not Radioresistant: Slowly but Continuing Shrinkage of the Tumor After Stereotactic Body Radiation Therapy.

Authors:  Satoshi Funayama; Hiroshi Onishi; Kengo Kuriyama; Takafumi Komiyama; Kan Marino; Masayuki Araya; Ryo Saito; Shinichi Aoki; Yoshiyasu Maehata; Hotaka Nonaka; Licht Tominaga; Juria Muramatsu; Hiroshi Nakagomi; Manabu Kamiyama; Masayuki Takeda
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

Review 9.  Stereotactic Ablative Radiotherapy for the Treatment of Clinically Localized Renal Cell Carcinoma.

Authors:  Scott P Campbell; Daniel Y Song; Phillip M Pierorazio; Mohamad E Allaf; Michael A Gorin
Journal:  J Oncol       Date:  2015-11-11       Impact factor: 4.375

10.  Stereotactic Body Radiotherapy for the Treatment of Renal Tumors.

Authors:  Michael Hanzly; Terrance Creighton; Michael Mix; Kevin Zeeck; Simon Fung-Kee-Fung; Anurag K Singh; Thomas Schwaab
Journal:  Urol Case Rep       Date:  2014-06-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.